Trial Profile
Real-life Effectiveness of Vortioxetine in Patients With Major Depressive Disorder: Non-interventional, Multi-national, Prospective Cohort Study to Assess Real-life Effectiveness of Vortioxetine
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Vortioxetine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Acronyms RELIEVE
- Sponsors Lundbeck A/S
- 01 Mar 2023 Results of a subgroup analysis (n=180) of the RELIEVE study assessing the effectiveness of vortioxetine treatment in patients with MDD and co-morbid GAD published in the Journal of Psychopharmacology
- 18 Oct 2022 Results assessing effectiveness and safety data of vortioxetine in real-world clinical practice from patients from Italy, presented at the 35th Annual Congress of the European College of Neuropsychopharmacology.
- 05 Oct 2021 Results assessing real-life effectiveness of vortioxetine as routine clinical treatment for MDD on functioning, depressive symptoms, cognitive symptoms, and health-related quality of life (HRQoL), presented at the 34th Annual Congress of the European College of Neuropsychopharmacology.